Bristol-Myers Squibb Company (BMY)
Bristol-Myers Squibb Company Retained Earnings: 33.60B
- Accounts Payable
- Accounts Receivable
- Accruals Pro
- Altman Z-Score Pro
- Asset Utilization
- Beneish M-Score Pro
- Beta Pro
- Book Value
- Book Value per Share
- Capital Expenditures
- Cash Conversion Cycle Pro
- Cash Div. Payout Ratio TTM Pro
- Cash Financing
- Cash Financing TTM
- Cash Investing
- Cash Investing TTM
- Cash Operations
- Cash Operations TTM
- Cash and Equivalents
- Cash and ST Investments
- Current Ratio
- Days Inventory Outstanding Pro
- Days Payable Outstanding Pro
- Days Sales Outstanding Pro
- Debt to Equity Ratio
- Dividend
- Dividend Yield
- EBITDA Margin TTM Pro
- EBITDA TTM Pro
- EV / EBIT Pro
- EV / EBITDA Pro
- EV / Free Cash Flow Pro
- EV / Revenues Pro
- Earnings Per Share
- Earnings Per Share Growth
- Earnings Per Share TTM
- Earnings Yield
- Effective Tax Rate TTM Pro
- Enterprise Value
- Expenses
- Expenses TTM
- Free Cash Flow
- Free Cash Flow TTM
- Free Cash Flow Yield Pro
- Fundamental Score Pro
- Gross Profit Margin
- Gross Profit TTM
- Income from Cont. Ops Pro
- Interest Expense
- Interest Income
- Inventories
- KZ Index Pro
- Liabilities
- Long Term Debt
- Market Cap
- Net Income
- Net Income TTM
- Net PP&E
- Operating Earnings Yield Pro
- Operating Margin TTM Pro
- Operating PE Ratio Pro
- Other Comprehensive Income Pro
- PE 10 Pro
- PE Ratio
- PE Value Pro
- PEG Ratio
- PS Value Pro
- Payout Ratio TTM Pro
- Price
- Price / Book Value
- Price / Sales Ratio
- Price / Tangible Book Value Pro
- Profit Margin
- R&D Expense
- Receivables Turnover
- Retained Earnings
- Retained Earnings Growth
- Return on Assets
- Return on Equity
- Return on Invested Capital Pro
- Revenue Growth
- Revenue Per Share TTM
- Revenues
- Revenues TTM
- SG&A Expense
- Shareholders Equity
- Shares Outstanding
- Stock Buybacks
- Tangible Book Value Pro
- Tangible Book Value Per Share Pro
- Tangible Common Equity Ratio Pro
- Times Interest Earned TTM Pro
- Total Assets
- Total Return Price
- Valuation (Historical Mult.) Pro
- Valuation Percentage Pro
- Value Score Pro
- Accounts Payable
- Accounts Receivable
- Accruals Pro
- Altman Z-Score Pro
- Asset Utilization
- Beneish M-Score Pro
- Beta Pro
- Book Value
- Book Value per Share
- Capital Expenditures
- Cash Conversion Cycle Pro
- Cash Div. Payout Ratio TTM Pro
- Cash Financing
- Cash Financing TTM
- Cash Investing
- Cash Investing TTM
- Cash Operations
- Cash Operations TTM
- Cash and Equivalents
- Cash and ST Investments
- Current Ratio
- Days Inventory Outstanding Pro
- Days Payable Outstanding Pro
- Days Sales Outstanding Pro
- Debt to Equity Ratio
- Dividend
- Dividend Yield
- EBITDA Margin TTM Pro
- EBITDA TTM Pro
- EV / EBIT Pro
- EV / EBITDA Pro
- EV / Free Cash Flow Pro
- EV / Revenues Pro
- Earnings Per Share
- Earnings Per Share Growth
- Earnings Per Share TTM
- Earnings Yield
- Effective Tax Rate TTM Pro
- Enterprise Value
- Expenses
- Expenses TTM
- Free Cash Flow
- Free Cash Flow TTM
- Free Cash Flow Yield Pro
- Fundamental Score Pro
- Gross Profit Margin
- Gross Profit TTM
- Income from Cont. Ops Pro
- Interest Expense
- Interest Income
- Inventories
- KZ Index Pro
- Liabilities
- Long Term Debt
- Market Cap
- Net Income
- Net Income TTM
- Net PP&E
- Operating Earnings Yield Pro
- Operating Margin TTM Pro
- Operating PE Ratio Pro
- Other Comprehensive Income Pro
- PE 10 Pro
- PE Ratio
- PE Value Pro
- PEG Ratio
- PS Value Pro
- Payout Ratio TTM Pro
- Price
- Price / Book Value
- Price / Sales Ratio
- Price / Tangible Book Value Pro
- Profit Margin
- R&D Expense
- Receivables Turnover
- Retained Earnings
- Retained Earnings Growth
- Return on Assets
- Return on Equity
- Return on Invested Capital Pro
- Revenue Growth
- Revenue Per Share TTM
- Revenues
- Revenues TTM
- SG&A Expense
- Shareholders Equity
- Shares Outstanding
- Stock Buybacks
- Tangible Book Value Pro
- Tangible Book Value Per Share Pro
- Tangible Common Equity Ratio Pro
- Times Interest Earned TTM Pro
- Total Assets
- Total Return Price
- Valuation (Historical Mult.) Pro
- Valuation Percentage Pro
- Value Score Pro
Select a metric
Date range:
to
<Embed Chart>
Pro Save as Image
Pro Data Export
Copy the code below and paste
into the embed destination.
into the embed destination.
Attention
OK
BMY Retained Earnings Rankings
| Overall | 98th percentile | 47 of 4165 |
| Sector | 99th percentile | 4 of 495 in Healthcare |
| Industry | 82nd percentile | 4 of 23 in Drug Manufacturers - Major |
BMY Retained Earnings Range, Past 5 Years
| Minimum | 19.76B | Dec 2007 |
| Maximum | 33.60B | Mar 2012 |
| Average | 26.69B |
About Retained Earnings
The net income that remains after paying dividends. It is reported on the balance sheet as the cumulative sum of each year's retained earnings over the life of the business. Retained earnings can be used to pay debt and future dividends, or can be reinvested into business activities.
Learn More
You may also be interested in these BMY related companies
BMY News
Amylin (AMLN) Shares Jump as Bids Due Today, Sanofi (SNY), Merck (MRK) Said to Make First-Round Bids
May 25, 2:01PM Street Insider
May 25, 2:01PM Street Insider
@Urbane_Gorilla http://stks.co/3z5t $CYCC $CELG $BMY $REGN $PFE #ASCO12 checklist
about 3 days ago by biotech
about 3 days ago by biotech
RT @ianestepan $CLDX if this data was from $BMY,$ONXX,$MDVN,$DNA or $PFE - people would be soooooo excited....
about 4 days ago by N0M0NEY_N0H0NEY
about 4 days ago by N0M0NEY_N0H0NEY
News related to $BMY, currently +0.5% since open: 'Bristol-Myers says FDA clears Mass. plant' http://stks.co/3q1B
about 12 days ago by TradeBot
about 12 days ago by TradeBot
Six Suitors Join $BMY in Considering a Bid for $AMLN http://stks.co/3psG
about 12 days ago by abubnic
about 12 days ago by abubnic
The Drama Continues At $AMLN: Takeover Still Likely. $BMY $LLY $SNY http://stks.co/3prL
about 12 days ago by abubnic
about 12 days ago by abubnic
Bristol-Myers (BMY) Announces FDA Approval of Devens, MA Plant for Manufacture of ORENCIA
May 15, 11:17AM Street Insider
May 15, 11:17AM Street Insider
U.S. FDA Approves Bristol-Myers Squibb Devens Biologics Manufacturing Facility
May 15, 11:01AM Benzinga
May 15, 11:01AM Benzinga
U.S. FDA Approves Bristol-Myers Squibb Devens Biologics Manufacturing Facility for Production of ORENCIA® (abatacept)
May 15, 11:00AM Business Wire
May 15, 11:00AM Business Wire
NR7 (EOD): Potential bullish NR7. Entry: 33.31. First Target: 34.00. $BMY http://chart.ly/qwxxeih
about 15 days ago by jackdamn
about 15 days ago by jackdamn
$BMY Ipilimumab,also known as MDX-010 or MDX-101 $DNDN Provenge along with $ARNA and $VVUS have been and are my Phamas for the next yr
about 16 days ago by selectstock
about 16 days ago by selectstock
Bristol-Myers Squibb to Present at Bank of America Merrill Lynch Health Care Conference
May 10, 11:00AM Business Wire
May 10, 11:00AM Business Wire
Huf Post: Two Drugs Harness Immune System To Fight Cancer. http://stks.co/3iDa $DNDN $BMY $AZN $ONTY $GSK
about 20 days ago by abubnic
about 20 days ago by abubnic
Listen to $BMY Bristol-Myers Squibb at Deutsche Bank AG Health Care Conference - live at 10:40 AM, ondemand after - http://stks.co/3hTs
about 21 days ago by earningscast
about 21 days ago by earningscast
@russwm thanks working hard here. above 34 is a desc trend break + above 10day. needs to hold 50day $BMY http://chart.ly/mghypbo
about 26 days ago by TraderNewburgh
about 26 days ago by TraderNewburgh
@TraderNewburgh I would love to hear your thoughts on $BMY in the short/medium term, if you have the time. Love your videos.
about 26 days ago by russwm
about 26 days ago by russwm
Listen to $BMY Bristol-Myers Squibb Annual Meeting of Stockholders - live at 10:00 AM, ondemand after - http://stks.co/3bIu
about 27 days ago by earningscast
about 27 days ago by earningscast
http://stks.co/3XIO Health Care Report Take A Look $FURX $BMY $AMLN
about 31 days ago by Stockmarketman2
about 31 days ago by Stockmarketman2
Recent Quotes
| Symbol | Price | Chg | Chg % | Market Cap |
|---|---|---|---|---|
| BMY | 33.09 | +0.10 | +0.30% | 55.84B |
| BMTI | 2.43 | +0.02 | +0.83% | 68.36M |
| BMRN | 38.64 | +0.13 | +0.34% | 4.468B |
| BMJ | 0.93 | +0.00 | +0.00% | |
| BMI | 36.69 | -0.25 | -0.68% | 550.35M |
| BMC | 43.69 | +0.72 | +1.68% | 7.175B |
| BMA | 13.46 | -0.33 | -2.39% | 785.12M |
| BLX | 19.14 | -0.08 | -0.42% | 540.90M |
| BLV | 93.83 | +0.41 | +0.44% | |
| BLTI | 2.42 | +0.06 | +2.54% | 74.27M |
